Get started
Author

Elena Élez

Observed names: E Elez (13628065), E Elez Fernández, E. Elez, E. Elez Fernandez, E. Elez Fernández, E. Élez, Elez Fernández,E., Elez Fernández,E., Elez, E.
ORCID: 0000-0002-9178-0246
Observed ORCID: 0000-0002-9178-0246
OpenAlex ID: A5102898564
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
2017 · E. Sanz-Garcia, G. Argiles, et al. · Annals of Oncology · 302
PDF
Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers
2017 · L. Diaz, A. Marabelle, et al. · Annals of Oncology · 65
Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
2019 · L.A. Diaz, D. Le, et al. · Annals of Oncology · 45
LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
2020 · A. Grothey, J. Tabernero, et al. · Annals of Oncology · 38
PDF
P-12 A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
2022 · T. André, E. Van Cutsem, et al. · Annals of Oncology · 13
723O Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: Final results of the PEGASUS trial
2025 · S. Marsoni, M. Prisciandaro, et al. · Annals of Oncology · 12
396O Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
2020 · T. André, M. Amonkar, et al. · Annals of Oncology · 10
432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
2021 · D.T. Le, L. Diaz, et al. · Annals of Oncology · 6
P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens
2020 · J. Tabernero, E. Elez Fernandez, et al. · Annals of Oncology · 5
Artificial intelligence combining radiomics and clinical data for predicting response to immunotherapy
2019 · M. Ligero, A. Garcia-Ruiz, et al. · Annals of Oncology · 5
LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW
2025 · S. Lonardi, H.J. Lenz, et al. · Annals of Oncology · 3
PDF
O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
2021 · T. André, K. Shiu, et al. · Annals of Oncology · 3
PDF
VHIO-300 and a thousand and one nights: A tale of precision medicine
2019 · G. Caratù, F.M. Mancuso, et al. · Annals of Oncology · 3
728MO Predictive value of low-frequency resistance mutations and relative mutant allele frequencies (rMAFs) in anti-EGFR rechallenge for RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
2025 · P. Mascaró Baselga, F. Salvà Ballabrera, et al. · Annals of Oncology · 2
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
2022 · A. Fernández Montes, E. Élez, et al. · Clinical & Translational Oncology · 2
AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
2018 · M. Español Rego, V. Alonso, et al. · Annals of Oncology · 2
Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
2018 · I. Matos Garcia, A. Azaro, et al. · Annals of Oncology · 2
21P Advancing tertiary lymphoid structure assessment in metastatic colorectal cancer with multiplex immunohistochemistry and digital pathology
2025 · G. Serna, C. Vaghi, et al. · Immuno-Oncology Technology · 1
802P Nous-209 immunotherapy with pembrolizumab for microsatellite instability high (MSI-H) metastatic colorectal cancer, refractory to anti-PD-1: Phase II trial results
2025 · F.J. Ros Montana, E. Elez Fernandez, et al. · Annals of Oncology · 1
809P Safety profile associated with first-line (1L) encorafenib plus cetuximab (EC) ± mFOLFOX6 and chemotherapy (chemo) ± bevacizumab (bev) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) (BREAKWATER)
2025 · V. Morris, E. Elez Fernandez, et al. · Annals of Oncology · 1
Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients
2025 · F. Salvà, G. Catani, et al. · ESMO Gastrointestinal Oncology · 1
PDF
42P Real-world outcomes of anti-EGFR rechallenge in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
2025 · P. Mascaró Baselga, F. Salvà Ballabrera, et al. · Annals of Oncology · 1
PDF
479MO Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
2025 · E. Elez Fernandez, E. Garralda, et al. · Annals of Oncology · 1
PDF
36P BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6
2025 · T. Yoshino, S. Kopetz, et al. · Annals of Oncology · 1
PDF
18P Combined analysis of plasmatic mutant allele fraction (pMAF) and RECISTv1.1 in MSI metastatic colorectal cancer (mCRC) treated with immune-checkpoint inhibitors (ICI)
2025 · F.J. Ros Montana, V. Navarro, et al. · Annals of Oncology · 1
PDF
Works count: 70
Citation count: 530
H-index: 7
I10-index: 7
Year
Topic
Type